Aptevo Therapeutics (APVO) Payables (2016 - 2023)
Historic Payables for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $4.0 million.
- Aptevo Therapeutics' Payables rose 2334.26% to $4.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.0 million, marking a year-over-year increase of 2334.26%. This contributed to the annual value of $3.5 million for FY2022, which is 106.87% up from last year.
- Per Aptevo Therapeutics' latest filing, its Payables stood at $4.0 million for Q3 2023, which was up 2334.26% from $4.9 million recorded in Q2 2023.
- Aptevo Therapeutics' Payables' 5-year high stood at $12.1 million during Q3 2019, with a 5-year trough of $3.2 million in Q3 2022.
- In the last 5 years, Aptevo Therapeutics' Payables had a median value of $4.7 million in 2020 and averaged $5.5 million.
- As far as peak fluctuations go, Aptevo Therapeutics' Payables soared by 5204.46% in 2019, and later crashed by 6760.54% in 2020.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Payables stood at $6.4 million in 2019, then decreased by 13.15% to $5.6 million in 2020, then tumbled by 37.99% to $3.5 million in 2021, then rose by 1.07% to $3.5 million in 2022, then grew by 14.32% to $4.0 million in 2023.
- Its Payables stands at $4.0 million for Q3 2023, versus $4.9 million for Q2 2023 and $4.1 million for Q1 2023.